NCT04752566 - A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 8, 2021

Primary Completion Date

August 3, 2022

Study Completion Date

August 3, 2022

Conditions

Guillain-Barre Syndrome

Interventions

BIOLOGICAL

Eculizumab

Eculizumab will be administered via IV infusion once a week for 4 weeks.

DRUG

Placebo

Placebo will be administered via IV infusion once a week for 4 weeks.

Trial Locations (22)

113-8519

Research Site, Bunkyō City

260-0877

Research Site, Chiba

814-0180

Research Site, Fukuoka

730-8518

Research Site, Hiroshima

890-8520

Research Site, Kagoshima

350-8550

Research Site, Kawagoe-shi

216-8511

Research Site, Kawasaki-shi

807-8555

Research Site, Kitakyushu-shi

650-0047

Research Site, Kobe

860-8556

Research Site, Kumamoto

710-8602

Research Site, Kurashiki-shi

390-8621

Research Site, Matsumoto-shi

181-8611

Research Site, Mitaka-shi

466-8560

Research Site, Nagoya

951-8520

Research Site, Niigata

663-8501

Research Site, Nishinomiya-shi

060-8648

Research Site, Sapporo

589-8511

Research Site, Sayama

983-8520

Research Site, Sendai

321-0293

Research Site, Shimotsuga-gun

755-8505

Research Site, Ube-shi

236-0004

Research Site, Yokohama